We are writing in reference to 2 articles published in Circulation Research, both of which report use of transgenic mice with smooth muscle cell-specific expression of the tetracycline-regulated transactivator (tTA) to activate conditional tTA-regulated alleles in the vasculature of transgenic mice. 1,2 The purpose of this letter is to report our experience with these mice and to inform the readership that, in our hands, these mice show no evidence of either (1) an ability to transactivate conditional alleles or (2) expression of the tTA in vascular tissue.
Regulated Transgene Expression in Vascular Smooth Muscle
To the Editor:
We are writing in reference to 2 articles published in Circulation Research, both of which report use of transgenic mice with smooth muscle cell-specific expression of the tetracycline-regulated transactivator (tTA) to activate conditional tTA-regulated alleles in the vasculature of transgenic mice. 1, 2 The purpose of this letter is to report our experience with these mice and to inform the readership that, in our hands, these mice show no evidence of either (1) an ability to transactivate conditional alleles or (2) expression of the tTA in vascular tissue.
Generation of mice in which a fragment of the murine SM22␣ promoter was used to achieve smooth muscle-specific expression of the tTA was first reported in abstract form in 1997 by Husain et al. 3 In 1998, experimental results obtained with these mice appeared in a figure contributed by Dr Husain to a review article in Circulation Research. 4 This figure depicted doubly transgenic SM22␣-tTA/tetO-␤-galactosidase (␤-gal) embryos and aortas harvested from adult doubly transgenic SM22␣-tTA/tetO-␤-gal mice. Incubation of the embryos with X-gal chromogen showed doxycycline-suppressible ␤-gal expression primarily in the heart and somites, with apparent faint staining in the vasculature. The X-gal-stained aortas showed sparse ␤-gal expression which was "inhibited" by doxycycline treatment.
Based on these reports, we requested these transgenic SM22␣-tTA mice for use in our own investigations. In 1999 Dr. Husain kindly sent us transgenic SM22␣-tTA mice derived from 2 independent lines. We were particularly appreciative of this generosity because at this time the SM22␣-tTA mice had not yet been reported in a peer-reviewed original research publication. To our surprise, however, we could not detect a functional SM22␣-tTA allele in these mice. Therefore, in 2000 we visited Dr Husain's laboratory, reviewed the data that his laboratory had obtained with the SM22␣-tTA mice, and presented our negative results to his group. Based on the data that we viewed at that time, we continued our work with the aforementioned 2 lines. We were also provided with a third, independently-generated line of SM22␣-tTA mice, which were said to have higher expression of the tTA than the other 2 lines.
In extensive experiments performed largely during the year 2000, but extending into 2001 to 2002, we found no evidence that the SM22␣-tTA mice could transactivate either of 2 tTA-regulated alleles that were proven, in our laboratory and elsewhere, 5 to be transactivated by the tTA expressed in ␣MHC-tTA transgenic mice (kindly provided by Dr Glenn Fishman). 6 We also found no evidence that the SM22␣-tTA mice expressed detectable levels of tTA in the aorta either by Western or Northern analysis. Since this time, 3 articles have appeared in which these SM22␣-tTA mice are reported to express tTA (based on RT-PCR, not by Northern or Western analysis) and to transactivate conditional alleles in the vasculature of adult mice. 1, 2, 7 Our uniformly negative results, which do not appear to be attributable to problems with assay sensitivity, contrast with these positive reports. Whether our results cast any doubt on the validity of these reports is best addressed by the authors of these reports.
We are submitting the primary data that report our experience with the SM22␣-tTA mice elsewhere, for consideration for publication as a peer-reviewed research article. We are optimistic that these data will be published in this format,* which would allow our fellow scientists to examine our methods and results closely, and compare them with the published record. 1, 2, 7 For now, this letter makes our central conclusions available promptly and directly to readers of the 2 articles in Circulation Research. These conclusions are likely of interest to the large number of investigators who are interested in generating or obtaining mice that have regulated transgene expression in the vasculature. We hope that this letter will stimulate further work which eventually leads to the generation of SM22␣-tTA (or similar) mice that are uniformly useful. *Note added in proof The primary data are in press: Lee S, Agah R, Xiao M, Frutkin AD, Kremen M, Shi H, Dichek DA. In vivo expression of a conditional TGF-␤1 transgene: no evidence for TGF-␤1 transgene expression in SM22-tTA transgenic mice. J Mol Cell Cardiol. In press.
Troubles With a Transgene: Experiences With SM22␣-tTA Mice
In response: Dr David Dichek and colleagues recount their disappointing experience with doxycycline (Dox)-responsive SM22␣-tTA "driver" mice provided to them. In constructing these animals, a 2.8-kb fragment of the SM22␣ promoter, generously provided by J. Miano and E. Olson, 1 was placed upstream of a tetracycline-responsive (Tet-OFF) transcriptional activator (tTA), generously provided by M. Gossen and H. Bujard. 2 Screening of founders was conducted in crosses with G3 reporter mice (tetO7-␤gal), generously provided by L. Hennighausen. 3 In 3 of 12 lines generated, nuclear X-gal staining was seen only in SM22␣-tTA ϩ /tetO7-␤gal ϩ mice, was responsive to Dox, and was consistently restricted to tissues known to support expression of the SM22␣ promoter in development, young adults (typically assessed Ͻ12 weeks of age), and after arterial injury. Although X-gal staining was patchy, varying in intensity between lines (#21, 19, 36, from weakest to strongest) and at different points in the arterial tree, it mirrored the fold-amplification of tTAdependent Luciferase activity in tetO7-luc reporter mice and correlated with levels of tTA expression, as determined by RT-PCR. 4
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Regarding articles appearing in Circulation Research, we first used line 36 SM22␣-tTA to drive expression of a dominant negative c-Myb (MEn) and ␤-gal. As previously detailed, we screened 7 MEn:␤-gal lines to discover 2 that could be activated by SM22␣-tTA. 5 MEn expression, ␤-gal activity, and the phenotypes documented were tTA-dependent, Dox-responsive, identical in both lines, and consistent with results of previous non-tissue-specific strategies targeting c-Myb. 5 We next screened 8 lines harboring a transgene encoding human PMCA4b and ␤-gal to find 2 that could be activated by SM22␣-tTA. 6 Again, hPMCA4b expression and the phenotype found was tTA-dependent, Dox-responsive, consistent in both lines, 6 and near identical to that reported independently. 7 No less rigor and precision were applied to the analysis of expression and phenotype of another line 36 SM22-tTA-dependent project published elsewhere. 8 Together, the above studies clearly indicate that a functional tTA was expressed in mice provided to Dr Dichek and colleagues. We can think of only a few possible explanations for why they were unable to observe tTA-dependent transgene expression with the same line, at the same time: (1) In their effector and reporter lines, the levels of SM22␣-driven tTA were insufficient to drive detectable expression of their transgenes. The need to screen several potential effector lines to find those that can be activated by tTA is well known 5,6,9 ; (2) Their dose and duration of Dox therapy were greater than what we later came to use. In both the MEn and hPMCA4b projects, Dox was used primarily in control groups treated with Dox. Once absence of embryonic lethality was confirmed, we did not routinely use Dox-suppression and withdrawal; (3) The animals studied were older than those in which we typically characterize phenotypes. In 2004, we observed in SM22␣-tTA ϩ /MEn:␤gal ϩ mice in the LDLr Ϫ/Ϫ background, that there was no detectable expression of MEn or ␤-gal after 3 to 6 months of a high-fat diet. Possible explanations for this included age-, diet/disease-, or strain-dependent repression of SM22␣ promoter activity.
In 2004, we submitted a manuscript to Circulation Research accounting the phenotype of line 36 SM22␣-tTA-dependent iNOS overexpression. Earlier, these data and our experience with a project involving line 36 SM22␣-tTA-dependent ET-1 overexpression were also presented at a Gordon Conference. 10 In both these projects, the levels of SM22␣-tTA-driven transgene expression were much lower than those observed with the corresponding lines in projects using ␣MHC-tTA mice, 11, 12 generously provided by G. Fishman. 13 As a corollary, levels of expression of the hPMCA4b:␤-gal transgene are much higher in crosses with ␣MHC-tTA 14 than those reported with SM22␣-tTA. 6 In both venues, we carefully detailed how the iNOS and ET-1 phenotypes were transient in nature with many elements being lost after 8 to 12 weeks of age or postnatal transgene activation. Together, these projects further suggested age-, effector-, or disease-dependent suppression of SM22␣-tTA.
Many investigators have studied regulatory elements of the SM22␣ and other SMC-specific promoters, 1, [15] [16] [17] [18] [19] but certain points deserve mentioning. First, as elegantly demonstrated by Regan et al, there exist dramatic differences between SM-MHC promoter-driven ␤-gal expression versus the "integrated" signal observed with SM-MHC promoter-driven Cre-mediated activation of a constitutive ␤-gal locus (ROSA26-␤-gal). 18 Thus, the heterogeneity of expression of transgenes driven by the SM22␣ promoter may mirror in part the spatially and temporally stochastic nature of VSMC-specific gene expression. Second, key elements within the SM22␣ promoter mediate loss of expression of genes under its regulation in disease states such as atherosclerosis. 19 Indeed, the remarkable phenotypic plasticity of SMC per se is known to be accompanied by changes in the levels of expression of its so called "marker" genes. 20 Accordingly, when we observed heterogeneous expression of SM22␣-tTAdriven transgenes under certain conditions and in specific crosses, we believed these instances primarily to be a function of these variables. However, in retrospect, they may also have been early signs of a more systematic "silencing."
In trying to respond to our Reviewers' comments on the iNOS project, we have found that line 36 SM22␣-tTA can no longer activate the iNOS transgene. Recent analyses show that our SM22-tTA lines no longer exhibit detectable levels of tTA expression by RT-PCR. Why independent SM22␣-tTA integration sites, previously active, have gone silent has regrettably become an area of our research. We do not believe this represents strain-dependent loss, inadvertent breeding-out, or rearrangement of a previously active integration site, as the SM22␣-tTA transgene has been in the C57Bl6 background for years, and we have not discerned changes by Southern blot. Our current hypothesis is that these lines have experienced progressive silencing of either the SM22␣ promoter or the bacterial and viral sequences encoding tTA, as a consequence of epigenetic factors that we hope to elucidate and report. Indeed, while many investigators anecdotally comment on the failure of various transgenes over time, a systematic accounting or analysis of these events and the mechanisms underlying them is lacking. Moreover, given our experiences with SM22␣-tTA mice, and other data regarding the SM-MHC-Cre animal, 21, 22 we wonder whether SMCspecific gene expression may be particularly prone to this phenomenon. As we rederive SM22␣-tTA animals, we are constructing newer reagents designed to be insulated from potential epigenetic modifications. Fortunately, other VSMC-specific conditional gene expression systems have been generated, 23, 24 which should, in a timelier manner, meet the needs of the cardiovascular research community for these valuable tools.
